What is the initial approach and antibiotic treatment for acute bacterial diarrhea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The initial approach to acute bacterial diarrhea should involve supportive care with fluid and electrolyte replacement, reserving antibiotics for patients with severe symptoms, immunocompromised status, or specific pathogens like Shigella, Campylobacter, or invasive Salmonella. When antibiotics are indicated, the first-line treatment is typically azithromycin 500 mg once daily for 3 days or ciprofloxacin 500 mg twice daily for 3-5 days, as recommended by the 2017 Infectious Diseases Society of America clinical practice guidelines 1. For suspected or confirmed Campylobacter, azithromycin is preferred due to increasing fluoroquinolone resistance, as supported by the guidelines for the prevention and treatment of travelers' diarrhea 1. Some key considerations for antibiotic selection include:

  • The likelihood of treatment efficacy and rapidity of response
  • Regional patterns of probable target pathogens and their antimicrobial resistance
  • Safety and tolerance profile of the antibiotic
  • Simplicity of treatment regimen and patient adherence
  • Cost It's also important to note that asymptomatic contacts of people with bloody diarrhea should not be offered empiric treatment, but should be advised to follow appropriate infection prevention and control measures 1. Additionally, people with clinical features of sepsis who are suspected of having enteric fever should be treated empirically with broad-spectrum antimicrobial therapy after blood, stool, and urine culture collection 1. In terms of specific antibiotic regimens, the following options are recommended:
  • Azithromycin 1000 mg by mouth or 500 mg by mouth, single or 1-day divided, 3-day course
  • Levofloxacin 500 mg by mouth, single dose or 3-day course
  • Ciprofloxacin 750 mg by mouth or 500 mg by mouth, single dose or 3-day course
  • Ofloxacin 400 mg by mouth, single dose or 3-day course
  • Rifaximin 200 mg by mouth three times daily, 3 days 1. However, it's essential to consider the potential risks and benefits of each antibiotic, including the risk of Clostridium difficile infection, and to choose the most appropriate treatment based on the individual patient's needs and circumstances.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Initial Approach to Acute Bacterial Diarrhea

  • The initial approach to acute bacterial diarrhea involves identifying the cause of the infection and assessing the severity of the symptoms 2.
  • Antibiotic therapy is considered for certain types of bacterial diarrhea, such as Clostridioides difficile infection (CDI) 3, 4, 5, 6.

Antibiotic Treatment for Acute Bacterial Diarrhea

  • For CDI, the antibiotics of choice are vancomycin, fidaxomicin, and metronidazole, although metronidazole is considered inferior 3.
  • Fidaxomicin has been shown to be superior to metronidazole and vancomycin for the treatment of initial episode, first recurrence, and non-severe CDI 4, 5.
  • Fidaxomicin is also associated with a lower risk of treatment failure and recurrence compared to vancomycin 5.
  • The American College of Gastroenterology (ACG) Clinical Guideline recommends an evidence-based approach to diagnosis, prevention, and treatment of acute diarrhea infection in adults 2.

Specific Antibiotic Regimens

  • Fidaxomicin 200 mg orally twice daily is a recommended regimen for the treatment of CDI 6.
  • Vancomycin 125 mg orally four times daily is also a recommended regimen for the treatment of CDI 6.
  • Metronidazole is considered inferior to fidaxomicin and vancomycin for the treatment of CDI 3, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clostridium difficile infection: review.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019

Research

Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021

Research

Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.